Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Evaluation of in vitro and in vivo Efficacy of a Novel Amphotericin B-Loaded Nanostructured Lipid Carrier in the Treatment of Leishmania braziliensis Infection

Full text
Author(s):
Reboucas-Silva, Jessica [1, 2] ; Tadini, Maraine Catarina [3, 4] ; Devequi-Nunes, Danielle [1, 5] ; Mansur, Ana Luiza [4] ; Silveira-Mattos, Paulo S. [1, 2] ; de Oliveira, Camila I. [2, 6] ; Formiga, Fabio R. [7, 8] ; Berretta, Andresa A. [9] ; Marquele-Oliveira, Franciane [4] ; Borges, Valeria M. [1, 2]
Total Authors: 10
Affiliation:
[1] Fundacao Oswaldo Cruz, Goncalo Moniz Inst, Lab Inflammat & Biomarkers, Salvador, BA - Brazil
[2] Fed Univ Bahia UFBA, Fac Med Bahia, Postgrad Program Pathol, Salvador, BA - Brazil
[3] Univ Sao Paulo, Dept Chem, Fac Philosophy Sci & Letters Ribeirao Preto, Ribeirao Preto, SP - Brazil
[4] Eleve Sci Res & Dev, Sao Paulo - Brazil
[5] SENAI Inst Innovat Adv Hlth Syst, Lab Pharmaceut Formulat, Salvador, BA - Brazil
[6] Fundacao Oswaldo Cruz, Lab Vector Borne Infect Dis, Goncalo Moniz Inst, Salvador, BA - Brazil
[7] Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Inst, Recife, PE - Brazil
[8] Univ Pernambuco UPE, Postgrad Program Appl Cellular & Mol Biol, Recife, PE - Brazil
[9] Apis Flora Ind & Comercial Ltda, Lab Res Dev & Innovat, Sao Paulo - Brazil
Total Affiliations: 9
Document type: Journal article
Source: INTERNATIONAL JOURNAL OF NANOMEDICINE; v. 15, p. 8659-8672, 2020.
Web of Science Citations: 0
Abstract

Background: Leishmaniasis is a neglected disease, and the current therapeutic arsenal for its treatment is seriously limited by high cost and toxicity. Nanostructured lipid carriers (NLCs) represent a promising approach due to high drug loading capacity, controlled drug release profiles and superior stability. Here, we explore the efficacy of a unique pH-sensitive amphotericin B-loaded NLC (AmB-NLC) in Leishmania braziliensis infection in vitro and in vivo. Methods and Results: AmB-NLC was assessed by dynamic light scattering and atomic force microscopy assays. The carrier showed a spherical shape with a nanometric size of 242.0 +/- 18.3 nm. Zeta potential was suggestive of high carrier stability (-42.5 +/- 1.5 mV), and the NLC showed similar to 99% drug encapsulation efficiency (EE%). In biological assays, AmB-NLC presented a similar IC50 as free AmB and conventional AmB deoxycholate (AmB-D) (11.7 +/- 1.73; 5.3 +/- 0.55 and 13 +/- 0.57 ng/mL, respectively), while also presenting higher selectivity index and lower toxicity to host cells, with no observed production of nitric oxide or TNF-alpha by in vitro assay. Confocal microscopy revealed the rapid uptake of AmB-NLC by infected macrophages after 1h, which, in association with more rapid disruption of AmB-NLC at acidic pH levels, may directly affect intracellular parasites. Leishmanicidal effects were evaluated in vivo in BALB/c mice infected in the ear dermis with L. braziliensis and treated with a pentavalent antimonial (Sb5+), liposomal AmB (AmB-L) or AmB-NLC. After 6 weeks of infection, AmB-NLC treatment resulted in smaller ear lesion size in all treated mice, indicating the efficacy of the novel formulation. Conclusion: Here, we preliminarily demonstrate the effectiveness of an innovative and cost-effective AmB-NLC formulation in promoting the killing of intracellular L. braziliensis. This novel carrier system could be a promising alternative for the future treatment of cutaneous leishmaniasis. (AU)

FAPESP's process: 15/15948-5 - Development and characterization of a nanomedicine, target driven, to leishmaniasis treatment
Grantee:Franciane Marquele de Oliveira
Support type: Research Grants - Innovative Research in Small Business - PIPE
FAPESP's process: 17/22888-4 - Development and characterization of target-driven nanotechnology based drug for Leishmaniasis treatment
Grantee:Franciane Marquele de Oliveira
Support type: Research Grants - Innovative Research in Small Business - PIPE
FAPESP's process: 16/10145-4 - Development and characterization of a nanomedicine, target driven, to leishmaniasis treatment
Grantee:Franciane Marquele de Oliveira
Support type: Scholarships in Brazil - Innovative Research in Small Business - PIPE